Ginkgo Bioworks Holdings, Inc. (DNA)
$
9.36
-0.55 (-5.88%)
Key metrics
Financial statements
Free cash flow per share
-3.3646
Market cap
511.2 Million
Price to sales ratio
2.8306
Debt to equity
0.7554
Current ratio
4.3900
Income quality
0.4883
Average inventory
0
ROE
-0.5355
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ginkgo Bioworks Holdings, Inc., along with its subsidiaries, specializes in developing a platform for cell programming that facilitates the biological production of various products such as novel therapeutics, food ingredients, and petroleum-derived chemicals. The company serves a diverse range of end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. As a testament to its operational performance, the company recorded an operating income of -$559,757,000.00 reflecting its earnings from core operations. The gross profit ratio is 0.83 showcasing the efficiency of the company's production and sales operations, while the gross profit stands at $188,494,000.00 highlighting its profitability from core activities. The company's stock is identified with the symbol 'DNA' in the market, and the operating income ratio is -2.47 indicating the company's operational profitability margin. Additionally, Ginkgo Bioworks has established a partnership with Selecta Biosciences, Inc. to advance the ImmTOR technology platform. Founded in 2008, the company is headquartered in Boston, Massachusetts. In the market landscape, the stock is affordable at $11.37 catering to budget-conscious investors. With a high average trading volume of 1,388,803.00 the stock indicates strong liquidity, making it an appealing option for traders. Ginkgo Bioworks, classified as a small-cap player with a market capitalization of $511,216,071.00 is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth while playing a vital role in shaping future developments in its field.
Is Ginkgo Bioworks Holdings, Inc. (DNA) a good investment?
Investing in Ginkgo Bioworks Holdings, Inc. (DNA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Ginkgo Bioworks Holdings, Inc. (DNA)'s stock forecast?
Analysts predict Ginkgo Bioworks Holdings, Inc. stock to fluctuate between $5 (low) and $17.58 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ginkgo Bioworks Holdings, Inc.'s market capitalization?
As of 2025-12-12, Ginkgo Bioworks Holdings, Inc.'s market cap is $511,216,071, based on 54,646,293 outstanding shares.
How does Ginkgo Bioworks Holdings, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Ginkgo Bioworks Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ginkgo Bioworks Holdings, Inc. (DNA) stock?
To buy Ginkgo Bioworks Holdings, Inc. (DNA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DNA. Place an order (Market, Limit, etc.).
What is the best time to invest in Ginkgo Bioworks Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Ginkgo Bioworks Holdings, Inc. stock ever split?
Ginkgo Bioworks Holdings, Inc.'s last stock split was 1:40 on 2024-08-20.
How did Ginkgo Bioworks Holdings, Inc. perform in the last earnings report?
Revenue: $227,043,000 | EPS: -$10.54 | Growth: -42.62%.
Where can I find Ginkgo Bioworks Holdings, Inc.'s investor relations reports?
Visit https://www.ginkgobioworks.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ginkgo Bioworks Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for Ginkgo Bioworks Holdings, Inc. stock?
All-time high: $634.56 (2021-11-09) | All-time low: $5 (2025-04-04).
What are the key trends affecting Ginkgo Bioworks Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
ProteoNic licenses its 2G UNic technology to Ginkgo Bioworks for a BARDA-backed consortium to boost fast, cost‑effective mAb production against filoviruses
accessnewswire.com
This strengthens NeuralCloud's expansion into the global wellness and B2B health practitioner delivery model with high-fidelity cardiac signal processing and digital health integration. Partnership positions MaxYield™ as a core AI engine for next-generation smart rings and consumer cardiac monitoring into the broader INTRINSICA platform.
prnewswire.com
BOSTON , Dec. 5, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has been awarded by the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory (PNNL) a four-year, up to $47M contract to co-design, build, and integrate a High‑Throughput Automated Phenotyping Platform (HTP‑APP) in support of the Microbial Molecular Phenotyping Capability (M2PC). The platform, selected through a competitive procurement process, is intended to enable the Department of Energy's (DOE) Office of Science, Biological and Environmental Research program to generate rich, reproducible microbial and microbiome data that ensure the U.S. remains at the forefront of the bioeconomy, safeguarding economic, societal, and national security benefits while maintaining global leadership in biotechnology innovation.
seekingalpha.com
Ginkgo Bioworks shares dropped on Friday as revenue growth continues to disappoint and cash burn persists despite improvements. Q3 results missed expectations, with adjusted revenues tumbling and operating losses jumping thanks to a non-recurring charge taken. DNA's working capital is at its lowest point since coverage began, and recent equity sales have led to over 13% dilution in 18 months.
seekingalpha.com
Ginkgo Bioworks Holdings, Inc. ( DNA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Daniel Waid Marshall Jason Kelly - Founder, CEO & Director Steven Coen - Chief Accounting Officer & CFO Presentation Daniel Waid Marshall [Audio Gap] Manager of Communications and Ownership at Ginkgo. I'm joined by Jason Kelly, our Co-Founder and CEO; and Steve Coen, our CFO.
benzinga.com
Illumina Inc. (NASDAQ:ILMN) stock is trading higher after the company reported better-than-expected third-quarter earnings.
zacks.com
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $12.74, signifying a -4.85% move from its prior day's close.
globenewswire.com
MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with a focus on off-the-shelf lentiviral vector (“LVV”) Plasmid DNA technology platform. This new agreement builds and expands on the existing successful partnership between the two companies, which has focused on the production of Plasmid DNA.
zacks.com
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.78, marking a -2.67% move from the previous day.
zacks.com
Ginkgo Bioworks Holdings, Inc. (DNA) reached $15.24 at the closing of the latest trading day, reflecting a -5.28% change compared to its last close.
See all news
